All In Biotech

Drug Trial Radar · NCT00704353

Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia

A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent

Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 735 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

735

Actual

Start

Jun 2008

Primary completion

Jul 2009

Study completion Mar 2011

Sponsor

Lead sponsor
American Regent, Inc.Industry
Sponsor type
Industry
First posted
Jun 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent

Conditions

  • Anemia

Interventions

  • Ferric CarboxymaltoseDrug

    15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.

  • Standard Medical Care (SMC)Drug

    Per product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)Time frame: through 30 days after the last dose of study drug (FCM or SMC for the treatment of IDA)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Luitpold Pharmaceuticals

    Norristown, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.